Novartis Expands Oncology Portfolio with US$1.5 B Acquisition of Myricx
By Sanya Sekhri
Pharma Deals Review: Vol 2026 Issue 8 (Table of Contents)
Published: 1 Aug-2026
DOI: 10.3833/pdr.v2026.i8.3029 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a strategic move to strengthen its oncology portfolio, Novartis has agreed to acquire Myricx for approximately US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS